Literature DB >> 24048441

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Christel Devaud1, Jennifer A Westwood1, Liza B John1, Jacqueline K Flynn1, Sophie Paquet-Fifield2, Connie P M Duong1, Carmen S M Yong1, Hollie J Pegram1, Steven A Stacker2, Marc G Achen2, Trina J Stewart1, Linda A Snyder3, Michele W L Teng1, Mark J Smyth1, Phillip K Darcy4, Michael H Kershaw4.   

Abstract

The tumor microenvironment can promote tumor growth and reduce treatment efficacy. Tumors can occur in many sites in the body, but how surrounding normal tissues at different anatomical sites affect tumor microenvironments and their subsequent response to therapy is not known.We demonstrated that tumors from renal, colon, or prostate cell lines in orthotopic locations responded to immunotherapy consisting of three agonist antibodies, termed Tri-mAb, to a much lesser extent than the same tumor type located subcutaneously. A tissue-specific response to Tri-mAb was confirmed by ex vivo separation of subcutaneous (SC) or orthotopic tumor cells from stromal cells, followed by reinjection of tumor cells into the opposite site. Compared with SC tumors, orthotopic tumors had a microenvironment associated with a type 2 immune response, related to immunosuppression, and an involvement of alternatively activated macrophages in the kidney model. Orthotopic kidney tumors were more highly vascularized than SC tumors. Neutralizing the macrophage- and Th2-associated molecules chemokine (C-C motif) ligand 2 or interleukin-13 led to a significantly improved therapeutic effect. This study highlights the importance of the tissue of implantation in sculpting the tumor microenvironment. These are important fundamental issues in tumor biology and crucial factors to consider in the design of experimental models and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048441      PMCID: PMC3978809          DOI: 10.1038/mt.2013.219

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  53 in total

1.  Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

Authors:  Michele W L Teng; Shin Foong Ngiow; Bianca von Scheidt; Nicole McLaughlin; Tim Sparwasser; Mark J Smyth
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection.

Authors:  Yi-Wei Li; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Qiang Gao; Yong-Sheng Xiao; Yong-Feng Xu
Journal:  J Hepatol       Date:  2010-10-01       Impact factor: 25.083

3.  Distinct macrophage phenotypes contribute to kidney injury and repair.

Authors:  Sik Lee; Sarah Huen; Hitoshi Nishio; Saori Nishio; Heung Kyu Lee; Bum-Soon Choi; Christiana Ruhrberg; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2011-02       Impact factor: 10.121

Review 4.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

5.  Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.

Authors:  Yoshihiro Komohara; Horlad Hasita; Koji Ohnishi; Yukio Fujiwara; Shinya Suzu; Masatoshi Eto; Motohiro Takeya
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

Review 6.  Alternative activation of macrophages: mechanism and functions.

Authors:  Siamon Gordon; Fernando O Martinez
Journal:  Immunity       Date:  2010-05-28       Impact factor: 31.745

7.  CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.

Authors:  Hernan Roca; Zachary S Varsos; Sudha Sud; Matthew J Craig; Chi Ying; Kenneth J Pienta
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

8.  Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.

Authors:  Jennifer A Westwood; Phillip K Darcy; Preethi Mayura Guru; Janelle Sharkey; Hollie J Pegram; Sally M Amos; Mark J Smyth; Michael H Kershaw
Journal:  J Transl Med       Date:  2010-04-28       Impact factor: 5.531

9.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

10.  IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.

Authors:  Mariola Kurowska-Stolarska; Bartosz Stolarski; Peter Kewin; Grace Murphy; Christopher J Corrigan; Sun Ying; Nick Pitman; Ananda Mirchandani; Batika Rana; Nico van Rooijen; Malcolm Shepherd; Charlie McSharry; Iain B McInnes; Damo Xu; Foo Y Liew
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

View more
  57 in total

1.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

2.  In vivo detection of the effects of preconditioning on LNCaP tumors by a TNF-α nanoparticle construct using MRI.

Authors:  Isabelle Iltis; Jeunghwan Choi; Manda Vollmers; Mithun Shenoi; John Bischof; Gregory J Metzger
Journal:  NMR Biomed       Date:  2014-07-01       Impact factor: 4.044

Review 3.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.

Authors:  Katherine A Murphy; Britnie R James; Andrew Wilber; Thomas S Griffith
Journal:  J Vis Exp       Date:  2017-04-12       Impact factor: 1.355

Review 5.  Complement in monoclonal antibody therapy of cancer.

Authors:  Laura M Rogers; Suresh Veeramani; George J Weiner
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Authors:  Janice K Laramy; Minjee Kim; Shiv K Gupta; Karen E Parrish; Shuangling Zhang; Katrina K Bakken; Brett L Carlson; Ann C Mladek; Daniel J Ma; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2017-08-28       Impact factor: 4.030

7.  β2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer.

Authors:  Aeson Chang; Caroline P Le; Adam K Walker; Sarah J Creed; Cindy K Pon; Sabine Albold; Dominic Carroll; Michelle L Halls; J Robert Lane; Bernhard Riedel; Davide Ferrari; Erica K Sloan
Journal:  Brain Behav Immun       Date:  2016-06-16       Impact factor: 7.217

8.  Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.

Authors:  Jessica J O'Konek; Elena Ambrosino; Anja C Bloom; Lise Pasquet; Chandirasegaran Massilamany; Zheng Xia; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 9.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

10.  Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles.

Authors:  Rodney Macedo; Juliette Rochefort; Maude Guillot-Delost; Kae Tanaka; Aline Le Moignic; Clara Noizat; Claude Baillou; Véronique Mateo; Antoine F Carpentier; Eric Tartour; Chloé Bertolus; Bertrand Bellier; Géraldine Lescaille; François M Lemoine
Journal:  Oncoimmunology       Date:  2016-07-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.